Transmucosal Delivery of Linagliptin for the Treatment of Type-2 Diabetes Mellitus by Ultra-Thin Nanofibers

被引:13
|
作者
Modgill, Vedant [1 ]
Garg, Tarun [1 ]
Goyal, Amit K. [1 ]
Rath, Goutam [1 ]
机构
[1] ISF Coll Pharm, Dept Pharmaceut, Moga 142001, Punjab, India
关键词
Anti-diabetic; nanofibers; polyvinyl alcohol; linagliptin; controlled release; BIOACTIVE DRUG MOLECULES; SCAFFOLDS; SYSTEMS; HYDROGEL;
D O I
10.2174/1567201811666141117144332
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of the present research was to cultivate an oral formulation of an anti-diabetic drug using polymeric nanofiber. A biodegradable polymer i.e. poly (vinyl alcohol) (PVA) nanofiber loaded linagliptin was prepared using electro spinning technique. The drug entrapment in the developed nanofibers was confirmed by scanning electron microscopy and X-ray diffraction. The in vivo study was performed on male Wistar rats to establish the pharmacodynamics behavior of developed formulation. The mucoadhesive strength results confirmed that the drug loaded PVA nanofiber patch had the highest mucoadhesion strength compare to PVA film and blank PVA nanofiber, due to its higher water holding capacity and surface area. The in vitro release study suggested that controlled release array of the drug from the nanofiber patch. In vivo activity validated the fact that linagliptin was delivered in its active state and showed visible results when compared to the commercial formulation. Additionally an encapsulation efficacy of 92% of the experimental formulation provides sufficient suggestion that the nanofibers serve as an ideal carrier for the delivery of linagliptin via the sublingual route.
引用
收藏
页码:323 / 332
页数:10
相关论文
共 50 条
  • [31] Linagliptin in the Management of Type 2 Diabetes Mellitus After Kidney Transplant
    Attallah, Nizar
    Yassine, Lina
    TRANSPLANTATION PROCEEDINGS, 2021, 53 (07) : 2234 - 2237
  • [32] Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
    Silke Retlich
    Vincent Duval
    Ulrike Graefe-Mody
    Christian Friedrich
    Sanjay Patel
    Ulrich Jaehde
    Alexander Staab
    Clinical Pharmacokinetics, 2015, 54 : 737 - 750
  • [33] Linagliptin A Review of its Use in the Management of Type 2 Diabetes Mellitus
    Deeks, Emma D.
    DRUGS, 2012, 72 (13) : 1793 - 1824
  • [34] Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials
    McGill, Janet B.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2012, 3 (04) : 113 - 124
  • [35] Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
    Retlich, Silke
    Duval, Vincent
    Graefe-Mody, Ulrike
    Friedrich, Christian
    Patel, Sanjay
    Jaehde, Ulrich
    Staab, Alexander
    CLINICAL PHARMACOKINETICS, 2015, 54 (07) : 737 - 750
  • [36] Linagliptin and Glimepiride Equally Effective for Adults with Type 2 Diabetes Mellitus
    Slawson, David C.
    AMERICAN FAMILY PHYSICIAN, 2020, 101 (05) : 309 - 310
  • [37] CORRELATION BETWEEN HOMOCYSTEINE AND TYPE-2 DIABETES MELLITUS COMPLICATIONS CORRELATION BETWEEN HOMOCYSTEINE AND TYPE-2 DIABETES MELLITUS COMPLICATIONS
    Akhvlediani, M.
    Emukhvari, M.
    Zabakhidze, N.
    Kvantaliani, T.
    ATHEROSCLEROSIS, 2016, 252 : E135 - E136
  • [38] Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations
    Ceriello, Antonio
    Inagaki, Nobuya
    JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (01): : 19 - 28
  • [39] Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus
    Tian, Feng
    Guo, Yali
    Zhou, Liping
    Yao, Qunying
    Liang, Xiaoyan
    Lu, Jiaxin
    He, Aiping
    Shen, Jie
    ARCHIVES OF MEDICAL SCIENCE, 2024, 20 (05) : 1407 - 1415
  • [40] Therapy of Type-1 and Type-2 Diabetes mellitus
    Weber, Sonja
    ERNAHRUNGS UMSCHAU, 2009, 56 (10): : 576 - 580